SCHEMBL5032076

SCHEMBL5032076

Cc1cc(-c2ncco2)sc1-c1ccc(C(N)=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 4/20 0.44
MKNK2 Q9HBH9 4/20 0.44
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
IL2 P60568 1/20 0.38
CAMKK2 Q96RR4 1/20 0.38
MYC P01106 3/20 0.38
LIMK1 P53667 1/20 0.38
MAP4K4 O95819 2/20 0.37
IKBKB O14920 1/20 0.36
MAPK1 P28482 1/20 0.36
MAP2K4 P45985 1/20 0.36
MAPKAPK2 P49137 1/20 0.36
MAPKAPK3 Q16644 1/20 0.36
MAPK6 Q16659 1/20 0.36
MAPKAPK5 Q8IW41 1/20 0.36
GPR52 Q9Y2T5 1/20 0.35
BRD4 O60885 1/20 0.35
BRD9 Q9H8M2 1/20 0.35
CDC7 O00311 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5033838 0.85 PRF1 (0.40) ESR1ESR2IL2LIMK1BRD4
SCHEMBL5032077 0.83 ESR1 (0.42) ESR1ESR2IL2KDM4ENPC1
SCHEMBL5033841 0.79 ESR1 (0.37) ESR1ESR2IL2MAP4K4KDM4E
SCHEMBL5029504 0.78 ESR1 (0.53) MKNK1MKNK2ESR1ESR2GPR52
SCHEMBL5033828 0.78 GPR52 (0.44) MKNK1MKNK2MYCMAP4K4IKBKB
SCHEMBL5789925 0.77 MKNK2 (0.51) MKNK1MKNK2MYCMAP4K4IKBKB
SCHEMBL5033802 0.77 AR (0.46) MKNK1MKNK2ESR1ESR2MAPK1
SCHEMBL5032068 0.77 CHEK2 (0.50) MKNK1MKNK2ESR1ESR2CAMKK2
SCHEMBL5033854 0.76 MYC (0.46) MKNK1MKNK2ESR1ESR2MYC
SCHEMBL5033803 0.74 ESR1 (0.48) MKNK1MKNK2ESR1ESR2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1983831-A2 PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2008-10-29 EP claimed
US-20070275960-A1 Phenyl and pyridyl compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-11-29 US claimed
WO-2007087429-A2 PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2007-08-02 WO claimed
EP-1983831-A2 PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2008-10-29 EP disclosed
US-20070275960-A1 Phenyl and pyridyl compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-11-29 US disclosed
WO-2007087429-A2 PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275960-A1 Phenyl and pyridyl compounds for inflammation and immune-related uses NLRP3, CCR1, NLRP1 MKNK1 3158/4885MKNK2 3557/4885ESR1 2368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.